Get the Stockscreener App
8.01
2.44%
-0.20
After Hours:
8.01
Aura Biosciences Inc stock is traded at $8.01, with a volume of 143.04K.
It is down -2.44% in the last 24 hours and down -2.55% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its lead candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$8.21
Open:
$8.22
24h Volume:
143.04K
Relative Volume:
0.83
Market Cap:
$400.11M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-4.1719
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
+1.01%
1M Performance:
-2.55%
6M Performance:
-9.29%
1Y Performance:
-2.20%
1-Day Range:
$7.925
$8.27
1-Week Range:
$7.61
$8.27
52-Week Range:
$6.63
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
8.01 | 400.11M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.16 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.07 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
657.97 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
278.25 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.94 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
How to Take Advantage of moves in (AURA) - Stock Traders Daily
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Up 20.8% in January - MarketBeat
Aura Biosciences (NASDAQ:AURA) Rating Increased to Strong-Buy at Lifesci Capital - MarketBeat
Lifesci Capital Upgrades Aura Biosciences (NASDAQ:AURA) to Strong-Buy - Defense World
JPMorgan Chase & Co. Grows Holdings in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Analysts Set Aura Biosciences, Inc. (NASDAQ:AURA) PT at $23.00 - Defense World
Regency Capital Management Inc. DE Sells 57,887 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Average Target Price from Brokerages - MarketBeat
What is Lifesci Capital’s Estimate for AURA FY2024 Earnings? - Defense World
FY2024 Earnings Forecast for AURA Issued By Lifesci Capital - MarketBeat
Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Aura Biosciences, Protara Therapeutics, Vaxiion Therapeutics - Barchart
This Insider Has Just Sold Shares In Aura Biosciences - Simply Wall St
Where are the Opportunities in (AURA) - Stock Traders Daily
Non Muscle Invasive Bladder Cancer Pipeline 2024: MOA, ROA, - openPR
Aura Biosciences VP Amy Elazzouzi sells $7,679 in stock - MSN
Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $122,374.85 in Stock - MarketBeat
Aura Biosciences CEO Elisabet de los Pinos sells shares worth $122,381 - MSN
Aura Biosciences VP Amy Elazzouzi sells $7,679 in stock By Investing.com - Investing.com Australia
Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update - MarketBeat
Barclays PLC Acquires 43,897 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Cool Company Ltd. (NYSE:CLCO) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Has $544,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of “Buy” from Brokerages - Defense World
(AURA) Trading Signals - Stock Traders Daily
Jane Street Group LLC Decreases Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews
Long Focus Capital Management, LLC Increases Stake in Aura Biosc - GuruFocus.com
Analysts Set Planet Labs PBC (NYSE:PL) Target Price at $4.33 - Defense World
Rush Street Interactive, Inc. (NYSE:RSI) Receives $12.43 Consensus PT from Analysts - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives $23.00 Consensus Price Target from Brokerages - Defense World
Talen Energy Corporation (NASDAQ:TLN) Receives $222.40 Average Target Price from Analysts - Defense World
Brokerages Set Innovative Industrial Properties, Inc. (NYSE:IIPR) Price Target at $104.50 - Defense World
Barclays PLC Buys 43,897 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Why Check-Cap Shares Are Trading Higher By Over 52%; Here Are 20 Stocks Moving Premarket - Benzinga
(AURA) Trading Advice - Stock Traders Daily
Geode Capital Management LLC Raises Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
State Street Corp Increases Stake in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
AB Volvo (publ) (OTCMKTS:VOLVF) Stock Price Up 0.3% – Still a Buy? - Defense World
Franklin Resources Inc. Has $15.57 Million Holdings in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Wellington Management Group LLP Takes $1.04 Million Position in Aura Biosciences, Inc. (NASDAQ:AURA) - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Holdings Lifted by Charles Schwab Investment Management Inc. - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Fmr LLC - MarketBeat
Aura Biosciences, Inc. (NASDAQ:AURA) Sees Significant Growth in Short Interest - MarketBeat
How the (AURA) price action is used to our Advantage - Stock Traders Daily
Learn to Evaluate (AURA) using the Charts - Stock Traders Daily
Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - GlobeNewswire
Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times
Aura Biosciences CEO to Present at Evercore ISI HealthCONx Conference | AURA Stock News - StockTitan
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):